Biotech Company Strengthens Strategic Intellectual Property Protection of Targeted Indication SAN DIEGO, June 29, 2022 /PRNewswire/ — Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the filing of a new provisional patent for…


Previous articleMindset Pharma Announces Development of Novel, Optimized, Intranasal Formulation
Next articleAlgernon Pharmaceuticals Announces Pricing of Public Offering of Units